Maynard Um
-
-
-
-
-
-
-
Moderna (MRNA) call put ratio 6.7 calls to 1 put with a focus on July 2 weekly 68 and 72 calls as share price up 11.5%
-
-
-
-
-
-
-
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
-
-
-
-
-
-
-
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
-
-
-
-
-
-
-
UBS Reiterates Neutral Rating on Moderna (MRNA)
-
-
-
-
-
-
-
WHO expects additional cases of hantavirus, but no wider outbreak seen
-
-
-
-
-
-
-
Moderna Is Working On Early-stage Hantavirus Vaccines - Bloomberg
-
-
-
-
-
-
-
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
-
414,840 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

